Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Biogen Idec Says Tysabri Patient Counts Are On The Upswing

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

But economy and competitive MS market could provide headwinds going forward.

You may also be interested in...



Biogen Idec/Acorda Strike Licensing Deal For MS Candidate Fampridine-SR

Biogen gains revenues, Acorda gets a strong partner well-entrenched in the EU MS market.

Biogen Idec/Acorda Strike Licensing Deal For MS Candidate Fampridine-SR

Biogen gains revenues, Acorda gets a strong partner well-entrenched in the EU MS market.

As Rumors About A Potential Acquisition Fly, Elan Names Two Dissidents To Its Board

Avoiding a proxy fight, the Irish firm placed two hostile members on its board, likely spelling trouble for CEO Martin.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Denmark Introduces Early Dialogue With Procurement Agency For Expensive Medicines

EU Biosimilar Filings, Opinions And Approvals

EMA To Address Challenges Of Using Organ-On-Chip Models In Drug Development

Biden Rx Pricing Plan Includes Antitrust Scrutiny, Patent ‘March-In’ Actions

See All
UsernamePublicRestriction

Register

PS069291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By